½ÃÀ庸°í¼­
»óǰÄÚµå
1426975

½Å°æÀÚ±Ø ±â±â ½ÃÀå ±Ô¸ð : Á¦Ç°º°, ¿ëµµº° ¹× ¿¹Ãø(2023-2032³â)

Neurostimulation Devices Market Size - By Product (Deep Brain, Gastric Electric, Spinal Cord, Sacral Nerve, Vagus Nerve Stimulator), By Application (Epilepsy, Pain Management, Essential Tremor, Urinary & Fecal Incontinence) & Forecast, 2023 - 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 111 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

½Å°æÀÚ±Ø ±â±â ½ÃÀåÀº ½Å°æÁúȯÀÇ À¯º´·ü Áõ°¡ ¹× °í·ÉÈ­ Àα¸ÀÇ Áõ°¡¸¦ ¹è°æÀ¸·Î 2024-2032³â 12.2% ÀÌ»óÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è³úÁ¹Á߱ⱸ(World Stroke Organization-Lancet Neurology Commission)ÀÇ ÀÚ·á¿¡ µû¸£¸é 2050³â±îÁö ³úÁ¹ÁßÀ¸·Î ÀÎÇÑ »ç¸ÁÀÚ ¼ö°¡ 50% Áõ°¡ÇÏ¿© ¸Å³â 970¸¸ ¸í¿¡ À°¹ÚÇÒ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖ½À´Ï´Ù.

±â¼ú Çõ½Å°ú È¿°úÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡µµ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ½Å°æ Àڱرâ´Â ´Ù¾çÇÑ ½Å°æ ÁúȯÀ» Ä¡·áÇÏ´Â µ¥ ÀÖÀ¸¸ç, ¸Å¿ì Áß¿äÇÑ ¼Ö·ç¼ÇÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù.

³ú½ÉºÎ ÀÚ±Ø ±â±â(DBS) ºÐ¾ß´Â 2032³â±îÁö Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Çõ½ÅÀûÀÎ ±â¼úÀº ³úÀÇ Æ¯Á¤ ºÎÀ§¿¡ Àü±â ÀÚ±ØÀ» ÁÖ´Â À̽ÄÇü Àåºñ¸¦ »ç¿ëÇÏ¿© ÆÄŲ½¼º´, º»Å¼º ÁøÀü, °£Áú°ú °°Àº ½Å°æ ÁúȯÀ» ¾Î°í Àִ ȯÀڵ鿡°Ô µµ¿òÀ» ÁÙ ¼ö ÀÖ´Â Çõ½ÅÀûÀÎ ±â¼úÀÔ´Ï´Ù. ÃÖ±Ù ³ú½ÉºÎÀڱر⠼ö¿ä°¡ Áõ°¡Çϰí ÀÖ´Â ÀÌÀ¯´Â ÀÚ±Ø ÆÐÅÏÀÇ Á¤È®µµ Çâ»ó°ú ¸ÂÃãÈ­, Ä¡·á °á°ú °³¼±, ºÎÀÛ¿ë ÃÖ¼ÒÈ­ µî Å« ÁøÀüÀÌ ÀÖ¾ú±â ¶§¹®ÀÔ´Ï´Ù.

ÆÄŲ½¼º´ ºÐ¾ß´Â ½Å°æÀÚ±Ø ±â±â°¡ Áõ»óÀ» °ü¸®Çϰí ȯÀÚÀÇ »îÀÇ ÁúÀ» °³¼±Çϴ ȹ±âÀûÀÎ ¹æ¹ýÀ¸·Î µîÀåÇÔ¿¡ µû¶ó 2032³â±îÁö ½ÃÀå¿¡¼­ ¸·´ëÇÑ ¸ÅÃâÀ» âÃâÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÆÄŲ½¼º´Àº ¶³¸², »»»»ÇÔ, ±ÕÇü Àå¾Ö¸¦ Ư¡À¸·Î ÇÏ´Â ÆÄŲ½¼º´Àº ȯÀڵ鿡°Ô ½É°¢ÇÑ ¹®Á¦¸¦ ¾ß±âÇÕ´Ï´Ù. ½Å°æÀÚ±Ø ±â±â´Â ÆÄŲ½¼º´ ȯÀÚÀÇ ¿îµ¿ Áõ»óÀ» ¿ÏÈ­Çϰí Àü¹ÝÀûÀÎ Çູ°¨À» Çâ»ó½ÃŰ´Â µ¥ È¿°úÀûÀÎ °ÍÀ¸·Î ÀÔÁõµÇ¾ú½À´Ï´Ù. ÀÌ ºÐ¾ßÀÇ ¿¬±¸°³¹ßÀÌ ÁøÇàµÊ¿¡ µû¶ó ÆÄŲ½¼º´ ¿ëµµ¿¡¼­ Á¦Ç° äÅÃÀÌ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

À¯·´ÀÇ ½Å°æÀÚ±Ø ±â±â ½ÃÀå ±Ô¸ð´Â ÀÇ·áºñ ÁöÃâ Áõ°¡, À¯¸®ÇÑ »óȯ Á¤Ã¥, ½Å°æ ÁúȯÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ 2032³â±îÁö Å©°Ô È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÁÖ¿ä ±â¾÷ ¹× ¿¬±¸ ±â°üÀÇ Çù·Â°ú ÇÔ²² Áö¿øÀûÀÎ ±ÔÁ¦ ȯ°æÀº ±â¼ú Çõ½ÅÀ» ÃËÁøÇϰí ÷´Ü ½Å°æ ÀÚ±Ø ±â¼ú ½ÃÀå °³Ã´À» ÃËÁøÇÏ¿©ÀÌ Áö¿ª ½ÃÀå Àü¸ÁÀ» Çü¼ºÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½Å°æÀÚ±Ø ±â±â »ê¾÷ ÀλçÀÌÆ®

  • COVID-19¿µÇ⠺м®
  • ¿¡ÄڽýºÅÛ ºÐ¼®
  • ±â¼ú »óȲ
  • ±ÔÁ¦ »óȲ
  • ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ÃËÁø¿äÀÎ
      • ¼±Áø±¹¿¡¼­ Àúħ½À¼ö¼úÀÇ ¼ö¿ä Áõ°¡
      • ½Å°æÁúȯÀÇ À¯º´·ü Áõ°¡
      • ½Å°æÀÚ±Ø ±â±âÀÇ ±â¼úÀû Áøº¸
      • ½Å°æÀå¾Ö¸¦ ¾Î´Â °í·É ȯÀÚÀÇ Áõ°¡
      • Àü ¼¼°èÀÇ ±â¾÷ ¹× Á¶Á÷¿¡ ÀÇÇÑ ÅõÀÚ
    • ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ© & °úÁ¦
      • ½Å°æÀÚ±Ø ±â±â¿¡ ¼ö¹ÝÇÏ´Â ÇÕº´Áõ
      • ¼÷·ÃµÈ ÇコÄɾî Á¾»çÀÚÀÇ ºÎÁ·
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • PorterÀÇ »ê¾÷ ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼­·Ð
  • ±â¾÷ Á¡À¯À² ºÐ¼®
  • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ °æÀï ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« Àü¸Á ¸ÅÆ®¸¯½º

Á¦5Àå ½Å°æÀÚ±Ø ±â±â ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Á¦Ç°º°

  • ÁÖ¿ä µ¿Çâ : Á¦Ç°º°
  • ³ú½ÉºÎ ÀÚ±Ø ±â±â
  • À§Àü±â Àڱرâ
  • ô¼ö Àڱرâ
  • õ°ñ½Å°æ Àڱرâ
  • ¹ÌÁֽŰæ Àڱرâ
  • °æÇÇÀû Àü±â ½Å°æÀÚ±Ø(TENS)
  • ±âŸ Á¦Ç°

Á¦6Àå ½Å°æÀÚ±Ø ±â±â ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ¿ëµµº°

  • ÁÖ¿ä µ¿Çâ : ¿ëµµº°
  • ÅëÁõ °ü¸®
  • °£Áú
  • º»Å¼ºÁøÀü
  • ¿ä½Ç±Ý¡¤º¯½Ç±Ý
  • ¿ì¿ïÁõ
  • ±ÙÀ°±äÀåÀÌ»ó
  • À§¸¶ºñ
  • ÆÄŲ½¼º´
  • ±âŸ ¿ëµµ

Á¦7Àå ½Å°æÀÚ±Ø ±â±â ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°

  • ÁÖ¿ä µ¿Çâ : Áö¿ªº°
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦8Àå ±â¾÷ °³¿ä

  • Abbott Laboratories
  • Aleva Neurotherapeutics S.A
  • BioControl Medical
  • Boston Scientific Corporation
  • ElectroCore, Inc.
  • Endostim
  • Helbling Holding AG
  • Innovative Health Solutions, Inc.
  • Laborie, Inc.
  • LivaNova PLC
  • Medtronic plc
  • MicroTransponder
  • Neuronetics, Inc.
  • Parasym Ltd.
  • RS Medical
  • Synapse Biomedical
  • tVNS Technologies GmbH(Cerbomed)
KSA 24.02.26

Neurostimulation devices market is anticipated to record more than 12.2% CAGR during 2024 and 2032, driven by the increasing prevalence of neurological disorders and a growing aging population. According to the data from A World Stroke Organization - Lancet Neurology Commission, the number of people dying from a stroke is expected to increase by 50%, reaching nearly 9.7 million deaths each year by 2050.

The technological innovations and a rising demand for effective treatment options are another driving force for market growth. Neurostimulation devices have emerged as a pivotal solution in addressing various neurological conditions.

The overall neurostimulation devices market is classified based on product, application, and region.

The Deep Brain Stimulator (DBS) segment is predicted to witness substantial growth through 2032. This innovative technology involves the use of implanted devices that deliver electrical stimulation to specific areas of the brain, offering relief for patients suffering from neurological disorders such as Parkinson's disease, essential tremor, and epilepsy. The significant advancements in recent years, with improved precision and customization of stimulation patterns, enhancing therapeutic outcomes and minimizing side effects are pushing the demand for deep brain stimulators.

The Parkinson's disease segment is expected to generate massive revenues in the market by 2032 as neurostimulation devices have emerged as a breakthrough in managing symptoms and improving the quality of life for patients. Parkinson's disease, characterized by tremors, stiffness, and impaired balance, poses significant challenges for those affected. Neurostimulation devices have proven to be effective in alleviating motor symptoms and enhancing the overall well-being of Parkinson's patients. As R&D in this field continue to advance, there will be increased product adoption in Parkinson's disease applications.

Europe neurostimulation devices market size will expand significantly through 2032, driven by the increasing healthcare expenditure, favorable reimbursement policies, and a rising prevalence of neurological disorders. The supportive regulatory environment, in consort with collaborations between key players and research institutions are fostering innovation and driving the development of advanced neurostimulation technologies, shaping the regional market outlook.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Base estimates & workings
  • 1.3 Forecast calculations
  • 1.4 Data Sources
    • 1.4.1 Primary
    • 1.4.2 Secondary
      • 1.4.2.1 Paid sources
      • 1.4.2.2 Unpaid sources

Chapter 2 Executive Summary

  • 2.1 Global neurostimulation devices market 360 degree synopsis, 2018 - 2032
    • 2.1.1 Regional trends
    • 2.1.2 Product trends
    • 2.1.3 Application trends

Chapter 3 Neurostimulation Devices Industry Insights

  • 3.1 COVID- 19 impact analysis
  • 3.2 Industry ecosystem analysis
  • 3.3 Technology landscape
  • 3.4 Regulatory landscape
  • 3.5 Industry impact forces
    • 3.5.1 Growth drivers
      • 3.5.1.1 Increasing demand for minimally invasive surgery in developed countries
      • 3.5.1.2 Increasing prevalence of neurological disorders
      • 3.5.1.3 Technological advancements in neurostimulation devices
      • 3.5.1.4 Increasing number of elderly patients with neurological disorders
      • 3.5.1.5 Investments by companies and organizations across the globe
    • 3.5.2 Industry pitfalls & challenges
      • 3.5.2.1 Complications associated with neurostimulation devices
      • 3.5.2.2 Lack of skilled healthcare practitioners
  • 3.6 Growth potential analysis
    • 3.6.1 By product
    • 3.6.2 By application
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

  • 4.1 Introduction
  • 4.2 Company market share analysis, 2022
  • 4.3 Competitive analysis of major market players, 2022
  • 4.4 Competitive positioning matrix, 2022
  • 4.5 Strategic outlook matrix, 2022

Chapter 5 Neurostimulation Devices Market Size and Forecast, By Product, 2018-2032 (USD Million)

  • 5.1 Key trends, by product
  • 5.2 Deep brain stimulator
  • 5.3 Gastric electric stimulator
  • 5.4 Spinal cord stimulator
  • 5.5 Sacral nerve stimulator
  • 5.6 Vagus nerve stimulator
  • 5.7 Transcutaneous electrical nerve stimulation (TENS)
  • 5.8 Other products

Chapter 6 Neurostimulation Devices Market Size and Forecast, By Application, 2018-2032 (USD Million)

  • 6.1 Key trends, by application
  • 6.2 Pain management
  • 6.3 Epilepsy
  • 6.4 Essential tremor
  • 6.5 Urinary and fecal incontinence
  • 6.6 Depression
  • 6.7 Dystonia
  • 6.8 Gastroparesis
  • 6.9 Parkinson's disease
  • 6.10 Other applications

Chapter 7 Neurostimulation Devices Market Size and Forecast, By Region, 2018-2032 (USD Million)

  • 7.1 Key trends, by region
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 France
    • 7.3.4 Italy
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Latin America
    • 7.5.1 Brazil
    • 7.5.2 Mexico
    • 7.5.3 Rest of Latin America
  • 7.6 Middle East & Africa
    • 7.6.1 Saudi Arabia
    • 7.6.2 South Africa
    • 7.6.3 Rest of Middle East & Africa

Chapter 8 Company Profiles

  • 8.1 Abbott Laboratories
  • 8.2 Aleva Neurotherapeutics S.A
  • 8.3 BioControl Medical
  • 8.4 Boston Scientific Corporation
  • 8.5 ElectroCore, Inc.
  • 8.6 Endostim
  • 8.7 Helbling Holding AG
  • 8.8 Innovative Health Solutions, Inc.
  • 8.9 Laborie, Inc.
  • 8.10 LivaNova PLC
  • 8.11 Medtronic plc
  • 8.12 MicroTransponder
  • 8.13 Neuronetics, Inc.
  • 8.14 Parasym Ltd.
  • 8.15 RS Medical
  • 8.16 Synapse Biomedical
  • 8.17 tVNS Technologies GmbH (Cerbomed)
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦